Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals

医学 干粉吸入器 药代动力学 耐受性 吸入器 吸入 不利影响 加药 药理学 内科学 哮喘 麻醉
作者
Robert Wilson,A.G.B. Templeton,Claudia Leemereise,Rhena Eames,Edward Banham-Hall,Edith M. Hessel,Anthony Cahn
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:41 (6): 1214-1220 被引量:13
标识
DOI:10.1016/j.clinthera.2019.04.008
摘要

Purpose Nemiralisib, a phosphoinositide 3-kinase δ inhibitor, is being investigated as an immunomodulatory agent with anti-inflammatory properties in chronic obstructive pulmonary disease. This study evaluated the pharmacokinetic (PK) properties and safety of a new formulation of nemiralisib that contains 0.4% magnesium stearate. Methods In this randomized, double-blind, parallel-group study, healthy individuals received a single dose of 500 or 750 μg of nemiralisib administered via the Ellipta dry powder inhaler (DPI) (n = 6 in each treatment group). Aerodynamic particle size distribution (APSD) data comparing previous and new formulations were available before the study. Serial PK analyses for plasma exposure and safety assessments were performed during the first 24 h after dosing, with follow-up measurements on days 3 and 6 in clinic. Findings APSD had increases of approximately 6-fold and 2-fold in very fine particle mass and fine particle mass over the previous (Diskus) formulation. In humans, systemic exposure (AUC) was greater after inhalation of 750 versus 500 μg of nemiralisib (AUC0–t: 17,200 h∙pg/mL; 95% CI, 10,900–27,200 h∙pg/mL and 13,100; 95% CI, 8130–21,000 h∙pg/mL, respectively). A low frequency of individual adverse events and no serious adverse events were reported after both doses. Implications After single-dose inhalation of 500 and 750 μg of nemiralisib from the Ellipta DPI in healthy individuals, plasma PK data were well defined, and as predicted based on previous PK and APSD data, exposure was increased with the new formulation. Nemiralisib was well tolerated with no new safety issues identified. These data supported progression of nemiralisib to a Phase IIb study in patients with chronic obstructive pulmonary disease. ClinicalTrials.gov identifier: NCT03189589.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
orixero的应助被xushanqi采纳,获得10
刚刚
萧雅发布了新的文献求助20
1秒前
磷酸盐完成签到,获得积分20
1秒前
芒果凤梨气泡美式的应助被lby采纳,获得10
1秒前
爆米花的应助被Paz采纳,获得10
1秒前
Tang发布了新的文献求助10
1秒前
wl321完成签到,获得积分10
1秒前
清03完成签到,获得积分10
2秒前
一叶知秋完成签到,获得积分10
2秒前
2秒前
2232发布了新的文献求助10
2秒前
2秒前
看不见的蛋炒饭完成签到 ,获得积分10
2秒前
Colin发布了新的文献求助10
3秒前
mayu发布了新的文献求助10
3秒前
3秒前
小二郎的应助被sugkook采纳,获得10
3秒前
3秒前
3秒前
3秒前
F1y的应助被烧飞狗采纳,获得30
3秒前
3秒前
乎乎完成签到,获得积分10
4秒前
小鱼完成签到,获得积分10
4秒前
何何完成签到 ,获得积分10
4秒前
大树努力要毕业完成签到,获得积分10
4秒前
深情安青的应助被笨笨的凝雁采纳,获得30
4秒前
4秒前
丘比特的应助被琉璃苣采纳,获得10
4秒前
5秒前
vv发布了新的文献求助10
5秒前
5秒前
研友_VZG7GZ的应助被binli采纳,获得10
5秒前
6秒前
希望天下0贩的0的应助被Uline采纳,获得10
6秒前
6秒前
lin发布了新的文献求助10
7秒前
晨晨发布了新的文献求助10
7秒前
我是老大的应助被Yahooo采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154662
求助须知:如何正确求助?哪些是违规求助? 9551195
关于积分的说明 21703319
捐赠科研通 7743946
什么是DOI,文献DOI怎么找? 3425903
关于科研通互助平台的介绍 2551038
邀请新用户注册赠送积分活动 2469573